WO2004112721A3 - Prevention or treatment of deficits that arise in connection with diseases of, or injuries to, the nervous system - Google Patents

Prevention or treatment of deficits that arise in connection with diseases of, or injuries to, the nervous system Download PDF

Info

Publication number
WO2004112721A3
WO2004112721A3 PCT/US2004/019759 US2004019759W WO2004112721A3 WO 2004112721 A3 WO2004112721 A3 WO 2004112721A3 US 2004019759 W US2004019759 W US 2004019759W WO 2004112721 A3 WO2004112721 A3 WO 2004112721A3
Authority
WO
WIPO (PCT)
Prior art keywords
injuries
nervous system
deficits
diseases
arise
Prior art date
Application number
PCT/US2004/019759
Other languages
French (fr)
Other versions
WO2004112721A2 (en
Inventor
Victor Arvanian
Lorne Mendell
Howard J Federoff
William J Bowers
Original Assignee
Univ Rochester
Univ New York
Victor Arvanian
Lorne Mendell
Howard J Federoff
William J Bowers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rochester, Univ New York, Victor Arvanian, Lorne Mendell, Howard J Federoff, William J Bowers filed Critical Univ Rochester
Publication of WO2004112721A2 publication Critical patent/WO2004112721A2/en
Publication of WO2004112721A3 publication Critical patent/WO2004112721A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention includes compositions and methods for use in, for example, maintaining or increasing synaptic plasticity, strengthening synaptic transmission, and/or treating or preventing motor, sensory, or cognitive deficits (including enhancing memory and learning). The compositions and methods of the invention can be used to treat, for example, injuries to the nervous system (such as spinal cord injuries), a variety of neural and neurodegenerative diseases, including those associated with dementia (e.g., Alzheimer's disease), and disorders that interfere with learning or impair memory.
PCT/US2004/019759 2003-06-20 2004-06-21 Prevention or treatment of deficits that arise in connection with diseases of, or injuries to, the nervous system WO2004112721A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48011203P 2003-06-20 2003-06-20
US60/480,112 2003-06-20

Publications (2)

Publication Number Publication Date
WO2004112721A2 WO2004112721A2 (en) 2004-12-29
WO2004112721A3 true WO2004112721A3 (en) 2006-03-23

Family

ID=33539260

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/019759 WO2004112721A2 (en) 2003-06-20 2004-06-21 Prevention or treatment of deficits that arise in connection with diseases of, or injuries to, the nervous system

Country Status (1)

Country Link
WO (1) WO2004112721A2 (en)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARVIAN VL AND MENDELL LM.: "Removal of NMDA Receptor Mg(2+) Block Extends the Action of NT-3 on Synaptic Transmission in Neonatal Rat Motoneurons.", J NEUROPHYSIOL., vol. 86, no. 1, July 2001 (2001-07-01), pages 123 - 129, XP002993652 *
HAASE G ET AL: "Gene Therapy of Murine Motor Neuron Disease Using Adenoviral Vectors for Neurotrophic Factors.", vol. 3, no. 4, April 1997 (1997-04-01), pages 429 - 436, XP002050329 *
MARSH DR ET AL: "Herpes Simplex Viral and Amplicon Vector-Mediated Gene Transfer Into Glia and Neurons in Organotypic Spinal Cord and Dorsal Root Ganglion Cultures.", MOLEC THERAP., vol. 1, no. 5, May 2000 (2000-05-01), pages 464 - 478, XP002993653 *

Also Published As

Publication number Publication date
WO2004112721A2 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
EP2698166A3 (en) Complement inhibition for improved nerve regeneration
IL225192A (en) Combination of dextromethorphan and quinidine for use in the treatment of mental illness, neuropathic pain or brain injury
WO2007127475A3 (en) Pyridazines for demyelinating diseases and neuropathic pain
WO2002036829A3 (en) Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries
DE60142236D1 (en) SUBSTITUTED 5-ALKINYL-PYRIMIDINES WITH NEUROTROPHIC EFFECT
CY1116933T1 (en) USE OF VEGF AND BONDS IN THE TREATMENT OF NEURAL DISORDERS
EP2039361A3 (en) Use of immunomodulatory compounds
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2005016893A3 (en) 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
WO2005039504A3 (en) Compounds and methods for treating toll-like receptor 2-related diseases and conditions
MX2009007410A (en) Inhibitors of d-amino acid oxidase.
WO2011011330A3 (en) Inhibitors of d-amino acid oxidase
HK1087351A1 (en) Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
NO20054913D0 (en) Use of clustein for the treatment and / or prevention of peripheral neurological disorders
EP2353606A3 (en) Compositions and methods for the treatment of CNS injuries
WO2004110359A3 (en) Fusion proteins for the treatment of cns
WO2008086452A3 (en) Treatment and prevention of alzheimer's disease
WO2007092165A3 (en) Compositions and methods for enhancing neuronal plasticity and regeneration
WO2005046605A3 (en) Compositions and methods of treating neurological diseases
WO2004112721A3 (en) Prevention or treatment of deficits that arise in connection with diseases of, or injuries to, the nervous system
WO2003092701A3 (en) Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders
WO2003045315A3 (en) Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
ATE394122T1 (en) INHIBITION OF THE CD95 LIGAND/RECEPTOR SYSTEM FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND INJURIES
WO2003037260A3 (en) Methods and compositions for treating parkinson's disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase